General Information of Drug Therapeutic Target (DTT) (ID: TTPS3C0)

DTT Name Aurora kinase A (AURKA)
Synonyms
hARK1; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase 15; Serine/threonine kinase 15; STK6; STK15; IAK1; Breast tumor-amplified kinase; BTAK; Aurora/IPL1-related kinase 1; Aurora-related kinase 1; Aurora-A; Aurora 2; AYK1; AURA; ARK1; ARK-1; AIRK1; AIK
Gene Name AURKA
DTT Type
Clinical trial target
[1]
BioChemical Class
Kinase
UniProt ID
AURKA_HUMAN
TTD ID
T87675
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.11.1
Sequence
MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRVPLQ
AQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKN
EESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRR
EVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITEL
ANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEM
IEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLI
SRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS
Function
Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis. Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression.
KEGG Pathway
Oocyte meiosis (hsa04114 )
Reactome Pathway
Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942 )
APC/C (R-HSA-174178 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
16 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AT9283 DMQ94CT Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
MLN8237 DMO8PT9 Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [3]
ENMD-2076 DMJZVPB Acute myeloid leukaemia 2A60 Phase 2 [4]
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [4]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
LY3295668 DM8RJTB Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
AMG 900 DMASGXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
CYC116 DMUMHXT Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
MK-5108 DMFGYKS Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
MLN8054 DMUANF3 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
R763 DME0CJ9 Haematological malignancy 2B33.Y Phase 1 [11]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
TAS-119 DMJXBVP Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
VIC-1911 DMDFC2Y Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Clinical Trial Drug(s)
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-03814735 DMO4S6T Advanced solid tumour 2A00-2F9Z Discontinued in Phase 1 [4]
------------------------------------------------------------------------------------
9 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-(1H-pyrazol-3-yl)-1H-benzimidazole DMHSORL Discovery agent N.A. Investigative [15]
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF Discovery agent N.A. Investigative [16]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [17]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [17]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [17]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [17]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [17]
Phosphonothreonine DMTFHPI Discovery agent N.A. Investigative [18]
ZM-447439 DMFP8WE Discovery agent N.A. Investigative [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2C82 Bone marrow 9.41E-46 -1.78 -2.05
Prostate cancer 2C82 Prostate 6.68E-08 1.47 1.84
------------------------------------------------------------------------------------

References

1 Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
2 A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
3 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
4 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6 Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
7 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
8 Clinical pipeline report, company report or official report of Cyclacel.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
10 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
11 Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
12 SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
13 TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268.
14 Clinical pipeline report, company report or official report of VITRAC Therapeutics.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
17 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem. 2006 Aug 10;49(16):4805-8.